NVIDIA Plans a $1.1 Billion Advance for U.S. Chip Testing Capacity - www.tokenpost.com

NVIDIA's $1.1B is not a capex line item—it is a sovereignty play on the final quality gate of AI silicon. The binding constraint in 2024-25 has migrated from wafer starts to back-end: CoWoS yield, HBM stacking verification, multi-die functional test. Internalizing test capacity domestically decouples NVIDIA's yield curve from geopolitical single points of failure. This is supply-chain architecture, not cost optimization. Competitively, AMD's MI300X and Intel's Gaudi 3 still route final test through Asian OSATs. NVIDIA's move carves out a 6-12 month "test-ready" delivery window. Expect ASE and Amkor to bid aggressively for U.S. expansion contracts within two quarters; bargaining power in back-end test is shifting toward the chip designer. The 12-24 month tail is where the structural break happens: HBM4's 16-hi stacking demands entirely new ATE architectures. Advantest and Teradyne face a bifurcated market—U.S.-compliant lines versus the rest. A "U.S. test premium" will emerge as a silent pricing lever in enterprise AI procurement, effectively splitting the same die into two parallel supply chains with different cost structures and delivery SLAs.